In vitro bactericidal activity of oxazolidinone, RBx 8700 against Mycobacterium tuberculosis and Mycobacterium avium complex.
RBx 8700, an investigational oxazolidinone, has excellent activity against respiratory pathogens. We evaluated the in vitro minimum inhibitory concentration (MIC) and bactericidal activity of RBx 8700 against Mycobacterium tuberculosis and Mycobacterium avium complex (MAC) isolates. RBx 8700 had an MIC of 1 gLg/ml against M. tuberculosis isolates resistant to both isoniazid (INH) and rifampicin (RIF), whereas its MIC against M. tuberculosis isolates resistant to either INH or RIF was 0.5 microg/ml.
Rao
M
M
Infectious Diseases, New Drug Discovery Research, Ranbaxy Research Laboratories, Plot No. 20, Sector 18, Udyog Vihar Industrial Area, Gurgaon-122 001, India. madhvi.rao@ranbaxy.com
Sood
R
R
Malhotra
S
S
Fatma
T
T
Upadhyay
D J
DJ
Rattan
A
A
D000995:Antitubercular Agents / Q000494:pharmacology; D002478:Cells, Cultured; D006801:Humans; D066298:In Vitro Techniques; D007538:Isoniazid / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D015269:Mycobacterium avium Complex / Q000187:drug effects*; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D023303:Oxazolidinones / Q000494:pharmacology*; D012293:Rifampin / Q000494:pharmacology
D000995:Antitubercular Agents; D023303:Oxazolidinones; C505880:RBX 8700; D007538:Isoniazid; D012293:Rifampin